Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, HC Wainwright Analyst Says

Replimune Group (NASDAQ:REPL) had its target price lifted by HC Wainwright from $17.00 to $21.00 in a report released on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other brokerages have also issued reports on REPL. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $19.14.

Replimune Group Trading Down 1.2 %

Shares of REPL stock opened at $13.59 on Wednesday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company’s 50-day moving average price is $12.28 and its 200-day moving average price is $11.33. The stock has a market cap of $929.83 million, a price-to-earnings ratio of -4.46 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, equities analysts predict that Replimune Group will post -2.88 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group during the second quarter worth about $57,000. Erste Asset Management GmbH acquired a new stake in shares of Replimune Group in the 3rd quarter valued at about $133,000. China Universal Asset Management Co. Ltd. grew its stake in Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after buying an additional 5,926 shares during the last quarter. BNP Paribas Financial Markets increased its position in Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after buying an additional 6,748 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Replimune Group in the third quarter valued at approximately $222,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.